Abstract 1576P
Background
In Italy, progress in lung cancer mortality in men is not paralleled by similar trends in women, though exposure to tobacco smoking is well known to be the key driver of lung cancer incidence and mortality. This study aimed to compare recent trends in lung cancer mortality rates in Italian men and women.
Methods
Mortality data for 2003-2019 were retrieved from death certificates compiled by the Italian National Institute for Statistics. These data were used to compute, separately in men and women, age-standardized mortality rates (/105/year) for lung cancer (ICD-10: C33-C34.9). Furthermore, we estimated the absolute number of prevented lung cancer deaths in 2007-2019 in Italy, as the difference between the observed and expected (based on the 2003-2006 mortality rates) number of lung cancer deaths. Data on the prevalence of tobacco smoking in men and women were collected from national surveys.
Results
In Italian men, the use of tobacco smoking strongly declined from 60% in the 1960s to 27.7% in 2021, whereas it tended to increase in women – particularly in the two last decades from 16.6% in 2004 to 20.7% in 2021. In men, a decline from 2007 to 2019 in lung cancer mortality rates was documented in all geographic areas (e.g., from 121.2/105 to 92.6/105 in northern Italy; and from 98.5/105 to 91.4/105 in southern Italy). Conversely, upward trends were registered for women: from 30.3/105 to 33.8/105 in the North; and from 16.3/105 to 20.3/105 in the South. From 2007 to 2019, there was an 18.7% reduction in the expected number of lung cancer deaths in men (-73.397) and an increase of 16.0% in expected deaths in women (+16.036).
Conclusions
Study findings strengthen the persistent need for tailoring interventions to reduce smoking among females to invert lung cancer mortality trends in Italian women.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Italian Ministry of Health, Ricerca Corrente IRCCS CRO, Aviano.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1553P - Access to EMA approved drugs in Europe, disparities across a border
Presenter: Orla Fitzpatrick
Session: Poster session 10
1554P - Co payments in cancer patients: Analysis and estimating OOP
Presenter: Krishnamani Kalpathi
Session: Poster session 10
1555P - Estimating the social value of immuno-oncology (IO) therapies in Japan
Presenter: Tomoya Ohno
Session: Poster session 10
1556P - Current landscape of drug approvals for genitourinary (GU) cancers in North America and Europe
Presenter: Jose Tapia
Session: Poster session 10
1557P - The use of patient experience in UK NICE decision making in oncology
Presenter: Noemi Muszbek
Session: Poster session 10
1558P - Independent validation of the Breast Cancer Risk Assessment Tool (Gail model) for predicting breast cancer risk in Egyptian population
Presenter: Elaria Yacoub
Session: Poster session 10
1559P - Equity of access and clinical impact of genomic testing in patients with cancer in a UK early phase clinical trials unit
Presenter: Jonathan Poon
Session: Poster session 10
1560P - Optimal age versus real age in breast and gynaecological risk reducing surgery in BRCA1/2 carriers
Presenter: Alberta Ferrari
Session: Poster session 10
1561P - Targeted screening methodologies to select high risk individuals: LungFlag performance in Estonia Lung Cancer Screening Pilot
Presenter: Tanel Laisaar
Session: Poster session 10
1562P - The feasibility of polygenic risk score-based population screening for breast cancer: The experience from the BRIGHT study in Estonia
Presenter: Anni Lepland
Session: Poster session 10